Cited 35 time in
The Role of CDK5 in Tumours and Tumour Microenvironments
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Do, Phuong Anh | - |
| dc.contributor.author | Lee, Chang Hoon | - |
| dc.date.accessioned | 2023-04-27T19:40:45Z | - |
| dc.date.available | 2023-04-27T19:40:45Z | - |
| dc.date.issued | 2021-01 | - |
| dc.identifier.issn | 2072-6694 | - |
| dc.identifier.issn | 2072-6694 | - |
| dc.identifier.uri | https://scholarworks.dongguk.edu/handle/sw.dongguk/5527 | - |
| dc.description.abstract | Simple Summary CDK5 is a serine/threonine type kinase that is mainly found in nerves. It is a target that has been studied primarily in neurological disorders, but recently it has been newly recognised for its importance in cancer. In this review, we mentioned the role of CDK5 in normal cells and the latest findings that CDK5 contributes to ten hallmarks of cancer and cancer-nerve connections. Also, we introduced representative CDK5 inhibitors and suggested the possibility of CDK5 inhibitors as treatments for refractory cancer. Cyclin-dependent kinase 5 (CDK5), which belongs to the protein kinase family, regulates neuronal function but is also associated with cancer development and has been proposed as a target for cancer treatment. Indeed, CDK5 has roles in cell proliferation, apoptosis, angiogenesis, inflammation, and immune response. Aberrant CDK5 activation triggers tumour progression in numerous types of cancer. In this review, we summarise the role of CDK5 in cancer and neurons and CDK5 inhibitors. We expect that our review helps researchers to develop CDK5 inhibitors as treatments for refractory cancer. | - |
| dc.format.extent | 27 | - |
| dc.language | 영어 | - |
| dc.language.iso | ENG | - |
| dc.publisher | MDPI | - |
| dc.title | The Role of CDK5 in Tumours and Tumour Microenvironments | - |
| dc.type | Article | - |
| dc.publisher.location | 스위스 | - |
| dc.identifier.doi | 10.3390/cancers13010101 | - |
| dc.identifier.scopusid | 2-s2.0-85098879933 | - |
| dc.identifier.wosid | 000605798400001 | - |
| dc.identifier.bibliographicCitation | CANCERS, v.13, no.1, pp 1 - 27 | - |
| dc.citation.title | CANCERS | - |
| dc.citation.volume | 13 | - |
| dc.citation.number | 1 | - |
| dc.citation.startPage | 1 | - |
| dc.citation.endPage | 27 | - |
| dc.type.docType | Review | - |
| dc.description.isOpenAccess | Y | - |
| dc.description.journalRegisteredClass | scie | - |
| dc.description.journalRegisteredClass | scopus | - |
| dc.relation.journalResearchArea | Oncology | - |
| dc.relation.journalWebOfScienceCategory | Oncology | - |
| dc.subject.keywordPlus | CYCLIN-DEPENDENT KINASE-5 | - |
| dc.subject.keywordPlus | NEURONAL CELL-CYCLE | - |
| dc.subject.keywordPlus | POLYAMINE CATABOLIC PATHWAY | - |
| dc.subject.keywordPlus | ENDOTHELIAL GROWTH-FACTOR | - |
| dc.subject.keywordPlus | LUNG-CANCER CELLS | - |
| dc.subject.keywordPlus | TRANSCRIPTION FACTOR | - |
| dc.subject.keywordPlus | ACTIVATOR P35 | - |
| dc.subject.keywordPlus | DNA-DAMAGE | - |
| dc.subject.keywordPlus | PANCREATIC-CANCER | - |
| dc.subject.keywordPlus | DOWN-REGULATION | - |
| dc.subject.keywordAuthor | CDK5 | - |
| dc.subject.keywordAuthor | cancer | - |
| dc.subject.keywordAuthor | neuron | - |
| dc.subject.keywordAuthor | microtubule | - |
| dc.subject.keywordAuthor | tumour microenvironments | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
30, Pildong-ro 1-gil, Jung-gu, Seoul, 04620, Republic of Korea+82-2-2260-3114
Copyright(c) 2023 DONGGUK UNIVERSITY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.
